Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL

X
Trial Profile

R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pixantrone (Primary) ; Cyclophosphamide; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms Pix in DLBCL first line
  • Most Recent Events

    • 17 Jun 2022 Results prospective and retrospective analysis assessing (n=28; between 2016 and 2021) efficacy and safety of first line R-CPOP in DLBCL patients with significant cardiac morbidity or high risk of anthracycline induced cardiotoxicity, presented at the 27th Congress of the European Haematology Association.
    • 24 Sep 2020 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
    • 30 Aug 2020 This trial has been completed in Austria, according to European Clinical Trials Database record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top